Inventaire - your friends and communities are your best library

mTOR signaling: new networks for ALL.

author

David A Fruman

published in: Blood

date of publication: 2016-06-01

language: English

Cites articles 10

Date

Title

Authors

2016-02-25

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Haiming Dai, Scott H Kaufmann, Martín E Fernández-Zapico
2015-02-27

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Jorge Eduardo Cortes, Susan O'Brien, Farhad Ravandi, Elias Jabbour, Marina Konopleva, Rebecca S Garris, Naval Daver, Lianchun Xiao, Michael E Rytting, Zhihong Zeng, Mary Ann Richie, Jan A Burger
2015-02-01

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells

Marina Y Konopleva
2013-04-03

Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)
2013-03-26

PUMA and BIM are required for oncogene inactivation-induced apoptosis

Shugaku Takeda
2012-12-01

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

Nahum Sonenberg
2010-09-08

Target of rapamycin signaling in leukemia and lymphoma
2010-03-01

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E
2010-01-13

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Marina Konopleva
2005-03-01

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells

René H. Medema, Silvia Fernández de Mattos, Inês Soeiro, Eric W-F Lam

Article - wd:Q42743076

Welcome to Inventaire

the library of your friends and communities

learn more